NCT00623441

E-Five Registry: A World-Wide Registry With The Endeavor Zotarolimus Eluting Coronary Stent

E-Five Registry: To Evaluate the 'Real World' Clinical Performance of the Medtronic Endeavor ABT-578 Eluting Coronary Stent System; A Prospective, Multicenter Registry

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 8,314 (actual)
• Sponsor: Medtronic Cardiac Rhythm and Heart Failure · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The safety and efficacy of the Endeavor(TM) ABT-578 Eluting Coronary Stent System has been assessed in a series of studies. The stent is coated with a proprietary drug compound that is designed to reduce restenosis. This prospective multi-center study has been initiated: * To document the acute and mid-term safety and overall clinical performance of the stent system in a "real world" patient population requiring stent implantation. * To assess the event rate in patient subgroups with specific clinical indications and/or vessel or lesion characteristics.

Conditions

• Coronary Artery Disease

Interventions

Type	Name	Description
DEVICE	Endeavor Zotarolimus Eluting Coronary Stent	Drug eluting stent

Timeline

• Start date: 2005-09-01
• Primary completion: 2007-11-01
• Completion: 2009-02-01
• First posted: 2008-02-26
• Last updated: 2015-11-23
• Results posted: 2011-12-16